Warren Buffett Is Selling Apple and Bank of America Stock and Piling Into an Embattled Healthcare Stock Down 46% This Year

Berkshire Hathaway's Q2 13F filing reveals a continued conservative investment posture, with the firm trimming 7% of its Apple stake and 4% of its Bank of America position, reflecting a broader pattern of reducing holdings amidst high valuations and potential economic concerns. Concurrently, Berkshire made a significant contrarian bet by initiating a new $1.57 billion position in UnitedHealth Group, an embattled healthcare insurer whose stock is down 46% this year due to rising costs and a DOJ probe. This move underscores Berkshire's value investing philosophy, seeing long-term potential in UNH's balance sheet strength, projected 2025 revenue growth, and attractive free cash flow yield despite near-term challenges.

Analysis

Berkshire Hathaway's second-quarter 13F filing reveals a dual strategy of continued defensive positioning and a significant contrarian investment. The firm's conservative stance is highlighted by the trimming of its largest holdings, reducing its Apple (AAPL) stake by 7% and its Bank of America (BAC) stake by 4%, bringing the total reduction over the past year to 30% and 41% respectively. This, coupled with hoarding cash and reducing share repurchases, suggests a cautious outlook on market valuations and potential economic headwinds, such as tariff-related issues for Apple and cyclical risks for banks. In a countermove, Berkshire initiated a substantial $1.57 billion position in UnitedHealth Group (UNH), an embattled healthcare insurer whose stock has fallen 46% this year. This investment epitomizes a value-based approach, looking past near-term challenges—including a downward revision of full-year EPS guidance to $16 due to $6.5 billion in higher medical costs and an ongoing DOJ investigation—to focus on long-term fundamentals. Berkshire likely sees value in UNH's projected double-digit revenue growth in 2025, its strong balance sheet where operating earnings cover interest expense over 7x, and its robust cash flow, evidenced by a trailing free-cash-flow yield above 10% that supports a recently increased 3.25% dividend.

Key Decisions for Investors

• Investors should note Berkshire's overall defensive posture, marked by sustained selling in market leaders Apple and Bank of America, as a signal of caution regarding high market valuations and potential macroeconomic headwinds.
• The new $1.57 billion stake in UnitedHealth suggests that for long-term value investors, the company's depressed valuation, strong free cash flow, and market leadership may outweigh significant near-term risks from cost pressures and regulatory scrutiny.
• Before following Berkshire into UnitedHealth, it is critical to monitor developments in the DOJ investigation and the company's management of medical cost trends, as these are the primary factors behind its recent underperformance.
• The significant reduction in Berkshire's Apple and Bank of America holdings warrants a review of positions in these stocks, particularly considering the articulated risks of tariffs and economic cyclicality.